<DOC>
	<DOCNO>NCT01775462</DOCNO>
	<brief_summary>This Phase 2 first-in-neonate EDI200 study enroll treatment-naïve , XLHED-affected male newborn first two week life . All subject meet entry criterion include documentation Ectodysplasin ( EDA ) mutation associate XLHED . Following Baseline evaluation , EDI200 dose initiate day-of-life 2 14 , study subject receive 2 doses/week total 5 dos . The study enroll subject two cohort subject cohort 1 dose 3 mg/kg/dose , associate partial efficacy , cohort 2 dose 10 mg/kg/dose enhance efficacy demonstrate relevant preclinical model . Given challenge identify family subject yet bear , expect cohort size time recruitment variable .</brief_summary>
	<brief_title>Phase 2 Study Evaluate Safety , Pharmacokinetics , Immunogenicity Pharmacodynamics/Efficacy EDI200 Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia ( XLHED )</brief_title>
	<detailed_description>This Phase 2 first-in-neonate EDI200 study enroll treatment-naïve , XLHED-affected male newborn first two week life . All subject meet entry criterion include documentation EDA mutation associate XLHED . Following Baseline evaluation , EDI200 dose initiate day-of-life 2 14 , study subject receive 2 doses/week total 5 dos . This dose regimen mirror use enhance efficacy dog XLHED model , consider relevant clinical study design . The study enroll subject two cohort subject cohort 1 dose 3 mg/kg/dose , associate partial efficacy , cohort 2 dose 10 mg/kg/dose enhance efficacy demonstrate relevant preclinical model . Given challenge identify family subject yet bear , expect cohort size time recruitment variable . The sponsor anticipate enrollment dose 6-10 subject 12-18 month period , 3-5 subject per cohort .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Ectodermal Dysplasia</mesh_term>
	<mesh_term>Ectodermal Dysplasia 1 , Anhidrotic</mesh_term>
	<criteria>Subjects study drug administration must meet follow criterion enrol : 1 . Male genetic confirmation XLHED diagnosis . 2 . Subject must least 48 hour age old 14 day . 3 . Subject reached term ( defined 37 week gestation older ) prior receive first dose study drug . 4 . Written inform consent parent ( reasonably available ) must obtain treatment XLHEDaffected male infant . 5 . Neither mother XLHEDaffected male infant know receive investigational study drug 9 month prior study subject enrollment study . 6 . No major medical issue PI considers contraindication participation . Siblings subject receive study drug must meet follow criterion enrol natural history substudy ( age limit involve ) : 1 . Provide write informed consent/assent . 2 . A full halfsibling study subject study subject receive least one dose study drug Phase 2 XLHED Neonate Study yet complete study . 3 . No major medical issue investigator considers contraindication participation . Subjects study drug administration meet follow criterion enrol study : 1 . Medically significant postnatal complication congenital anomaly outside consider associated diagnosis XLHED . Siblings subject receive study drug meet follow criterion enrol natural history substudy : 1 . Known hypersensitivity pilocarpine pilocarpinelike muscarinic agonist . 2 . Known hypersensitivity lidocaine lidocainelike agent . 3 . Presence pacemaker . 4 . Subjects able willing comply procedure protocol . 5 . Subject condition , opinion investigator would allow safe conduct study .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Days</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hypohidrotic Ectodermal Dysplasia</keyword>
	<keyword>XLHED</keyword>
</DOC>